JAK Janus Kinase
K |
|||
| (12 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | {{qt|Baricitinib}} | ||
| + | {{qt|Fedratinib}} | ||
| + | {{qt|Jaktinib}} | ||
| + | {{qt|Methotrexate}} | ||
| + | {{qt|Ruxolitinib}} | ||
| + | {{qt|Tofacitinib}} | ||
| + | {{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}} | ||
{{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}} | {{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}} | ||
{{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}} | {{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}} | ||
{{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}} | {{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}} | ||
| − | + | {{ttp|p=32535597|t=2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.|pdf=|usr=008}} | |
| − | + | {{tp|p=32385052|t=2020. ...The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}} | |
| − | + | {{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}} | |
| − | + | {{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=010}} | |
| − | {{tp|p= | + | {{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}} |
| − | + | {{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}} | |
| − | + | {{tp|p=32592721|t=2020. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysise.|pdf=|usr=018}} | |
| − | {{tp|p= | + | {{tp|p=32726783|t=2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.|pdf=|usr=017}} |
| − | {{tp|p= | + | {{tp|p=32789663|t=2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.|pdf=|usr=018}} |
| − | {{tp|p= | + | {{tp|p=32847819|t=2020. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.|pdf=|usr=019}} |
| − | + | {{tp|p=32918336|t=2020. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.|pdf=|usr=019}} | |
| − | + | {{tp|p=33187978|t=2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.|pdf=|usr=020}} | |
| − | + | {{ttp|p=33245005|t=2020. JAK-STAT pathway inhibition and their implications in COVID-19 therapy.|pdf=|usr=021}} | |
| − | + | {{tp|p=32779813|t=2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.|pdf=|usr=018}} | |
| − | {{ttp|p= | + | |
Aktuelle Version vom 11. April 2021, 19:59 Uhr
| PHA Biologicals |
| Baricitinib |
| Fedratinib |
| Jaktinib |
| Methotrexate |
| Ruxolitinib |
| Tofacitinib |
| 32584421 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. |
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
| 32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. |
32385052 2020. ...The potential role of JAK inhibitors in the management of COVID-19.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32580895 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
32592721 2020. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysise.
32726783 2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
32789663 2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.
32847819 2020. Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.
32918336 2020. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.
33187978 2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
| 33245005 2020. JAK-STAT pathway inhibition and their implications in COVID-19 therapy. |
32779813 2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.
